106 related articles for article (PubMed ID: 12089238)
1. Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact.
Bajetta E; Zilembo N; Bichisao E
J Clin Oncol; 2002 Jul; 20(13):3039-40; author reply 3040. PubMed ID: 12089238
[No Abstract] [Full Text] [Related]
2. Anastrozole--a new generation in aromatase inhibition: clinical pharmacology.
Dowsett M; Lønning PE
Oncology; 1997; 54 Suppl 2():11-4. PubMed ID: 9394854
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibition in obese women: how much is enough?
Ligibel JA; Winer EP
J Clin Oncol; 2012 Aug; 30(24):2940-2. PubMed ID: 22802318
[No Abstract] [Full Text] [Related]
4. Need for estradiol assays with a lower functional sensitivity in clinical studies examining postmenopausal women treated with aromatase inhibitors.
Pauwels S; Lintermans A; Neven P; Verhaeghe J; Jans I; Billen J; Vanderschueren D; Vermeersch P
J Clin Oncol; 2013 Feb; 31(4):509. PubMed ID: 23270000
[No Abstract] [Full Text] [Related]
5. Reply to S. Pauwels et al.
Folkerd EJ; Dixon JM; A' Hern RP; Dowsett M
J Clin Oncol; 2013 Feb; 31(4):509-10. PubMed ID: 23472261
[No Abstract] [Full Text] [Related]
6. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Geisler J; Haynes B; Anker G; Dowsett M; Lønning PE
J Clin Oncol; 2002 Feb; 20(3):751-7. PubMed ID: 11821457
[TBL] [Abstract][Full Text] [Related]
7. New breast cancer drug.
Brink S
US News World Rep; 2001 Dec; 131(26):52. PubMed ID: 11793594
[No Abstract] [Full Text] [Related]
8. Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects.
Smith IE; Norton A
Breast Cancer Res Treat; 1998; 49 Suppl 1():S67-71; discussion S73-7. PubMed ID: 9797020
[No Abstract] [Full Text] [Related]
9. Intratumoral aromatase model: the effects of letrozole (CGS 20267).
Brodie A; Lu Q; Yue W; Wang J; Liu Y
Breast Cancer Res Treat; 1998; 49 Suppl 1():S23-6; discussion S33-7. PubMed ID: 9797014
[TBL] [Abstract][Full Text] [Related]
10. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
Lewis S
Am Heart J; 2007 Feb; 153(2):182-8. PubMed ID: 17239675
[TBL] [Abstract][Full Text] [Related]
11. [Anastrozolo: intracellular anti-aromatase activity and pharmacologic interactions. Satellite Symposium AIOM 1999 - Roma].
Longo F; Mansueto G
Tumori; 1999; 85(6):A19-25. PubMed ID: 10774583
[No Abstract] [Full Text] [Related]
12. The relevance of preclinical models to the treatment of postmenopausal breast cancer.
Dukes M
Oncology; 1997; 54 Suppl 2():6-10. PubMed ID: 9394853
[TBL] [Abstract][Full Text] [Related]
13. [Evolvement of hormone therapy for breast cancer. Florence, March 14, 2001].
Longo F; Mansueto G
Tumori; 2001; 87(3):A6-14. PubMed ID: 11505951
[No Abstract] [Full Text] [Related]
14. Anti-aromatase agents in the treatment and prevention of breast cancer.
Goss P
Cancer Control; 2002; 9(2 Suppl):2-8. PubMed ID: 11965225
[TBL] [Abstract][Full Text] [Related]
15. Pictilisib Plus Anastrozole Reduces Proliferation in ER+ Breast Cancer.
Cancer Discov; 2016 May; 6(5):471. PubMed ID: 27012832
[TBL] [Abstract][Full Text] [Related]
16. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
[TBL] [Abstract][Full Text] [Related]
17. [Aromatase inhibitors: pharmacological aspects].
de Crémoux P
Bull Cancer; 2000 Dec; 87 Spec No():23-29. PubMed ID: 11250605
[TBL] [Abstract][Full Text] [Related]
18. Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women.
Dowsett M; Donaldson K; Tsuboi M; Wong J; Yates R
Cancer Chemother Pharmacol; 2000; 46(1):35-9. PubMed ID: 10912575
[TBL] [Abstract][Full Text] [Related]
19. Letrozole in breast cancer.
Shahab N
N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971058
[No Abstract] [Full Text] [Related]
20. Are differences in the available aromatase inhibitors and inactivators significant?
Johnson PE; Buzdar A
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4360s-4368s; discussion 4411s-4412s. PubMed ID: 11916226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
